Valuation: Novo Nordisk A/S

Capitalization 1,330B 210B 178B 163B 154B 287B 19,986B 289B 1,930B 754B 9,519B 787B 770B 32,954B P/E ratio 2026 *
13.2x
P/E ratio 2027 * 13.6x
Enterprise value 1,446B 228B 193B 177B 168B 312B 21,730B 314B 2,099B 820B 10,349B 855B 837B 35,829B EV / Sales 2026 *
4.97x
EV / Sales 2027 * 4.83x
Free-Float
71.44%
Yield 2026 *
3.84%
Yield 2027 * 3.75%
1 day+3.34%
1 week+7.91%
Current month+10.19%
1 month+24.66%
3 months-4.75%
6 months+1.80%
Current year-7.76%
1 week 282.8
Extreme 282.8
312.05
1 month 235.95
Extreme 235.95
312.05
Current year 224.25
Extreme 224.25
409.95
1 year 224.25
Extreme 224.25
533.4
3 years 224.25
Extreme 224.25
1,033.2
5 years 224.25
Extreme 224.25
1,033.2
10 years 109.1
Extreme 109.1
1,033.2
Manager TitleAgeSince
Chief Executive Officer 56 06/08/2025
Director of Finance/CFO 55 14/02/2018
Chief Tech/Sci/R&D Officer 56 06/08/2025
Director TitleAgeSince
Director/Board Member 61 22/03/2017
Director/Board Member 51 21/03/2018
Director/Board Member 61 23/03/2022
Change 5d. change 1-year change 3-years change Capi.($)
+3.34%+7.91%-32.48%-47.44% 203B
+1.95%+0.38%+31.64%+121.83% 846B
+0.05%-2.54%+43.58%+36.98% 533B
+0.61%-1.85%+9.85%+38.49% 356B
-0.94%-0.97%+22.40%+12.53% 324B
+1.18%-0.07%+31.86%+14.23% 282B
+0.30%-1.90%+25.07%+23.67% 278B
-0.09%-0.78%+46.48%-5.61% 275B
-0.64%-0.07%+23.97%+40.78% 179B
+1.67%+1.42%+37.78%+70.94% 163B
Average +0.56%-0.63%+24.01%+30.64% 343.84B
Weighted average by Cap. +0.32%-1.12%+27.15%+46.19%

Financials

2026 *2027 *
Net sales 291B 45.92B 38.93B 35.66B 33.75B 62.78B 4,376B 63.32B 423B 165B 2,084B 172B 169B 7,216B 299B 47.08B 39.91B 36.56B 34.6B 64.36B 4,486B 64.91B 433B 169B 2,137B 177B 173B 7,397B
Net income 97.23B 15.33B 13B 11.91B 11.27B 20.96B 1,461B 21.14B 141B 55.14B 696B 57.53B 56.32B 2,409B 95.11B 15B 12.72B 11.65B 11.02B 20.5B 1,429B 20.68B 138B 53.94B 681B 56.27B 55.09B 2,357B
Net Debt 116B 18.29B 15.51B 14.21B 13.44B 25.01B 1,744B 25.23B 168B 65.79B 830B 68.64B 67.2B 2,875B 113B 17.79B 15.08B 13.81B 13.07B 24.32B 1,695B 24.53B 164B 63.97B 807B 66.74B 65.34B 2,795B
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).
Employees
67,900
Date Price Change Volume
11/05/26 300.00 kr +3.34% 7,278,350
08/05/26 290.30 kr -1.76% 4,614,317
07/05/26 295.50 kr +0.85% 5,530,016
06/05/26 293.00 kr +2.48% 15,205,850
05/05/26 285.90 kr +1.04% 6,780,981
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
300.00DKK
Average target price
307.99DKK
Spread / Average Target
+2.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NOVO B Stock